Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastas
Go back to Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastas| (NASDAQ: PSTV) | Delayed: 3.78 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.78 | 52 Week High | $ | |||
| Open | $3.78 | 52 Week Low | $ | |||
| Day High | $3.78 | P/E | N/A | |||
| Day Low | $3.78 | EPS | $ | |||
| Volume | 5,456 | |||||
